ArticleArthritis research & therapy2025
Stepwise dose reduction and discontinuation of bDMARD in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markers.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of CAR-T cell therapy in orthopedics: From bone malignancies to non-malignant musculoskeletal disorders.Journal of orthopaedic translation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the clinical outcomes of stepwise dose-reduction and discontinuation protocols for biological disease-modifying anti-rheumatic drugs (bDMARD) in patients with stable rheumatoid arthritis (RA), and explored predictors of disease flares.
methodsSeventy-one patients in clinical remission for ≥ 6 months were enrolled in the Reduction group. In Phase 1, dosing intervals were extended to 1.5 and then 2.0 times the standard schedule for patients who maintained low disease activity (LDA) for ≥ 12 months. Patients who sustained LDA (n = 41) advanced to Phase 2 for complete bDMARD discontinuation. Seventy-one matched patients who continued standard therapy served as controls.
resultsIn Phase 1, 12-month flare-free population rates were 80.6% in the Reduction group and 87.1% in the control group. Adverse events leading to discontinuation were rare in both groups. Gray-scale ultrasound findings were associated with flares during dose reduction (Wald χ²=2.3, p = 0.04, OR 1.06). In Phase 2, 47.5% of patients experienced flares after bDMARD discontinuation, and the 24-month flare-free population rate was significantly lower in the Reduction group (52.5%) compared to controls (86.6%) (HR 4.6, 95% CI: 2.2-11.0, p < 0.001). Serious adverse events were infrequent and occurred only in the control group. Power Doppler scores and ACPA-positivity were predictive of flares, while concomitant methotrexate use reduced flare risk.
conclusionsTapering bDMARD may maintain disease control short-term, but discontinuation increases flare risk. Ultrasound findings and ACPA-positivity are valuable predictors, and concomitant methotrexate use may help prevent flares after discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.